
Opinion|Videos|January 5, 2026
Molecular Testing and Identifying Appropriate Patients for Lenvatinib Plus Pembrolizumab in Endometrial Cancer
Author(s)Ramez N. Eskander, MD
Endometrial cancer treatment evolves with molecular insights, enhancing patient outcomes through tailored therapies and innovative clinical trials.
Advertisement
Episodes in this series

Ramez N. Eskander, MD, discusses the heterogenous nature of endometrial cancer and molecular testing being used to identify appropriate patients for specific treatments. He also highlights what study results have shown regarding molecular testing and optimal use of lenvatinib plus pembrolizumab in endometrial cancer.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5































